Biotechnology Industry Retirement Agreements

The Registrant's Equity Award, Death, Disability and Retirement Policy (EXACT SCIENCES CORP, Filed With SEC on February 21, 2024)

Fifth Amendment to the Amgen Inc. Supplemental Retirement Plan, effective January 1, 2024 (Amgen Inc., Filed With SEC on February 14, 2024)

Retirement and Transition Agreement, dated September 28, 2023, by and between the Registrant and Nancy Simonian, M.D (Syros Pharmaceuticals, Inc., Filed With SEC on November 14, 2023)

Retirement and Transition Agreement by and between the Registrant and Gregory C. Critchfield, M.D., dated May 15, 2023 (SERA PROGNOSTICS, INC., Filed With SEC on August 9, 2023)

Castle Biosciences, Inc. Retirement Policy Approved January 13, 2023 (CASTLE BIOSCIENCES INC, Filed With SEC on February 28, 2023)

The Registrant's Equity Award, Death, Disability and Retirement Policy (EXACT SCIENCES CORP, Filed With SEC on February 21, 2023)

Fourth Amendment to the Amgen Inc. Supplemental Retirement Plan, effective October 20, 2022 (Amgen Inc., Filed With SEC on February 9, 2023)

Retirement Policy for Equity Awards (Intellia Therapeutics, Inc., Filed With SEC on August 4, 2022)

Retirement and Transition Agreement dated April 19, 2022, between the Company and Laura Clague (Retrophin, Inc., Filed With SEC on April 20, 2022)

Transition and Retirement Agreement by and between Gerald McMahon and the Registrant, dated as of October 25, 2021 (Harpoon Therapeutics, Inc., Filed With SEC on March 10, 2022)

Third Amendment to the Amgen Inc. Supplemental Retirement Plan, effective October 20, 2021 (Amgen Inc., Filed With SEC on February 16, 2022)

Retirement Agreement (vTv Therapeutics Inc., Filed With SEC on October 20, 2021)

Transition and Retirement Agreement between Brian G. Drazba and MEI Pharma, Inc., dated as of August 2, 2021 (MEI Pharma, Inc., Filed With SEC on August 5, 2021)

Retirement Agreement by and between CytomX Therapeutics, Inc and Dr. W. Michael Kavanaugh, dated as of December 1, 2020 (CytomX Therapeutics, Inc., Filed With SEC on February 24, 2021)

Form of Retirement Agreement, by and between Cyclacel Pharmaceuticals, Inc. and Judy H. Chiao, MD (Cyclacel Pharmaceuticals, Inc., Filed With SEC on February 24, 2021)

Transition and Retirement Agreement, dated January 13, 2020, by and between Arena and Steven W. Spector (ARENA PHARMACEUTICALS INC, Filed With SEC on February 23, 2021)

Retirement Agreement, dated August 31, 2020, between Galectin Therapeutics Inc. and Harold Shlevin (GALECTIN THERAPEUTICS INC, Filed With SEC on September 2, 2020)

Transition and Retirement Agreement, dated as of January 13, 2020, by and between Arena and Steven Spector (ARENA PHARMACEUTICALS INC, Filed With SEC on May 7, 2020)

Second Amendment to the Amgen Inc. Supplemental Retirement Plan (As Amended and Restated effective October 23, 2019) (Amgen Inc., Filed With SEC on February 12, 2020)

Retirement Agreement, dated December 13, 2019, among Casebia Therapeutics Limited Liability Partnership, Bayer HealthCare LLC, CRISPR Therapeutics AG and CRISPR Therapeutics, Inc (CRISPR Therapeutics AG, Filed With SEC on February 12, 2020)

Amended and restated retirement transition letter, dated July 1, 2019, between Prothena Biosciences Inc and A.W. Homan (Prothena Corp plc, Filed With SEC on November 5, 2019)

Retirement Agreement, by and between the Company and Dinah Sah, dated as of May 20, 2019 (Voyager Therapeutics, Inc., Filed With SEC on May 21, 2019)

Retirement transition letter, dated December 11, 2018, between Prothena Biosciences Inc and A. W. Homan (Prothena Corp plc, Filed With SEC on March 15, 2019)

Retirement Agreement, dated January 4, 2019, by and between the Company and Stephan Aselage (Retrophin, Inc., Filed With SEC on February 26, 2019)

Retirement Agreement, by and between Voyager Therapeutics, Inc. and Steven M. Paul, dated as of June 28, 2018 (Voyager Therapeutics, Inc., Filed With SEC on June 29, 2018)

Retirement Agreement, effective as of January 5, 2018, by and between Regeneron Pharmaceuticals, Inc. and Robert J. Terifay (Regeneron Pharmaceuticals, Filed With SEC on May 3, 2018)

TRANSITION, RETIREMENT AND RELEASE OF CLAIMS AGREEMENT (AVEO PHARMACEUTICALS INC, Filed With SEC on August 9, 2017)

MOMENTA PHARMACEUTICALS, INC. EQUITY AWARD RETIREMENT POLICY (Momenta Pharmaceuticals, Inc., Filed With SEC on May 5, 2017)

MOMENTA PHARMACEUTICALS, INC. EQUITY AWARD RETIREMENT POLICY (Momenta Pharmaceuticals, Inc., Filed With SEC on December 16, 2016)

FIRST AMENDMENT TO THE AMGEN INC. SUPPLEMENTAL RETIREMENT PLAN AS AMENDED AND RESTATED EFFECTIVE OCTOBER 16, 2013 (Amgen Inc., Filed With SEC on October 28, 2016)

RETIREMENT AGREEMENT AND MUTUAL GENERAL RELEASE (CYTRX CORP, Filed With SEC on July 29, 2016)

AMGEN INC. SUPPLEMENTAL RETIREMENT PLAN (As Amended and Restated Effective October 16, 2013) AMGEN INC. SUPPLEMENTAL RETIREMENT PLAN (As Amended and Restated Effective October 16,... (Amgen Inc., Filed With SEC on February 24, 2014)

FIFTH AMENDMENT TO THE AMGEN INC. SUPPLEMENTAL RETIREMENT PLAN AS AMENDED AND RESTATED EFFECTIVE JANUARY 1, 2009 (Amgen Inc., Filed With SEC on November 6, 2012)

FOURTH AMENDMENT TO THE AMGEN INC. SUPPLEMENTAL RETIREMENT PLAN AS AMENDED AND RESTATED EFFECTIVE JANUARY 1, 2009 (Amgen Inc., Filed With SEC on August 8, 2012)

THIRD AMENDMENT TO THE AMGEN INC. SUPPLEMENTAL RETIREMENT PLAN AS AMENDED AND RESTATED EFFECTIVE JANUARY 1, 2009 (Amgen Inc., Filed With SEC on February 29, 2012)

SECOND AMENDMENT TO THE AMGEN INC. SUPPLEMENTAL RETIREMENT PLAN AS AMENDED AND RESTATED EFFECTIVE JANUARY 1, 2009 (Amgen Inc., Filed With SEC on February 29, 2012)

AMGEN INC. EXECUTIVE NONQUALIFIED RETIREMENT PLAN (Amgen Inc., Filed With SEC on November 7, 2008)

AMGEN INC. SUPPLEMENTAL RETIREMENT PLAN (Amgen Inc., Filed With SEC on November 7, 2008)

FIFTH AMENDMENT TO THE AMGEN INC. SUPPLEMENTAL RETIREMENT PLAN (Amgen Inc., Filed With SEC on May 12, 2008)

FOURTH AMENDMENT TO THE AMGEN INC. SUPPLEMENTAL RETIREMENT PLAN (Amgen Inc., Filed With SEC on November 9, 2007)

Category

Industry

Companies

Contracts

Retirement Agreements in the Biotechnology Industry